NFKB1 and thyroid gland carcinoma: Since NF-κB is a main actor in aggressive thyroid carcinomas, given that it regulates many aspects of PDTC and ATC biology, novel therapeutic strategies to fight these tumors could be provided by targeting NF-κB transcriptional activity.